Pfiz­er dips its toe in­to fi­bro­sis and or­gan re­gen­er­a­tion, lead­ing raise ex­ten­sion for Bel­gium's Agomab

In ear­ly 2021, Bel­gian biotech Agomab Ther­a­peu­tics un­veiled a $74 mil­lion Se­ries B round to fund proof-of-con­cept stud­ies for its lead can­di­date. Over a year lat­er, the biotech has cul­ti­vat­ed an ad­di­tion­al $40.5 mil­lion to add to its Se­ries B — and bring a big name on board.

Phar­ma gi­ant Pfiz­er leads the ex­ten­sion with an in­vest­ment through its Break­through Growth Ini­tia­tive, which funds biotechs and lends them sci­en­tif­ic know-how, Agomab an­nounced Wednes­day morn­ing. The new cash brings the to­tal round to $114 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER